Mal-Lys(m-PEG4)-Val-Ala-PAB(m-PEG8)-MMAE peg4 196 SMILES: [2H]C([2H])([2H])C(=O)C1=CC=C(C)C=C1 Isotopic Enrichment:

196 SMILES: [2H]C([2H])([2H])C(=O)C1=CC=C(C)C=C1 Isotopic Enrichment: 98 atom % D Purity (HPLC): ≥ 95% Shipping Conditions: room temperature Storage Conditions: Refrigerated Regulatory Statement: For Research Use Only

544 SMILES [N-]=[N+]=NCCOCCOCCOCCOCCNC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Purity (HPLC) >= 95% Shipping Conditions Room temperature Storage Conditions Refrigerated Shelf Life 12 months after the date of delivery Regulatory Statement For Research Use Only

601 Purity (HPLC) >= 95% Physical Appearance Orange Solid Optical Properties Abs/Em Maxima: 494/526 nm Solubility DMSO

Trametinib (GSK1120212

Datasheet         MSDS        COA

Mal-Lys(m-PEG4)-Val-Ala-PAB(m-PEG8)-MMAE peg4 196 SMILES: [2H]C([2H])([2H])C(=O)C1=CC=C(C)C=C1 Isotopic Enrichment:SOLU KNEX cleavable linker features a Val Ala dipeptide. In this product, a Mal Lys(m PEG4) moiety replaces the conventional maleimidocaproyl (MC) unit to enhance aqueous solubility. Additionally, m PEG8 is attached to the commonly used self immolative para aminobenzyl (PAB) moiety to further increase aqueous solubility. The payload is monomethyl auristatin E (MMAE), a highly potent antimitotic agent that inhibits tubulin polymerization, leading to